Trump picks Dr. Marty Makary, a Johns Hopkins surgeon, for FDA chief
Makary, who will need to be confirmed by the Senate, has defended controversial Trump cabinet pick Robert F. Kennedy Jr.
Related Articles
Decode LLM Evaluation: Benchmarks, Metrics, and Leaderboards
This comprehensive LLM evaluation guide explains the importance of benchmarks, metrics, and leaderboards to measure LLM capabilities in real world applications.
Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling
Ogishi, Kitaoka, et al. examine humans deficient in PD-1 and PD-L1 as well as associated mouse models and find that PD-1 and PD-L1 promote B cell…
Glucose limitation protects cancer cells from apoptosis induced by pyrimidine restriction and replication inhibition
Nature Metabolism – Nam et al. show that limited glucose availability similar to the tumour microenvironment confers resistance against chemotherapeutic drugs that target DNA synthesis.
New study tests levels of chemicals linked to cancer in Pittsburgh-area water
We’ll show you how forever chemicals get from our homes to the water system and what’s being done to protect you, tonight on Channel 11…
Roche’s TIGIT prospect fails another phase 3 lung cancer test
Roche’s SKYSCRAPER-01 has fallen down. | Roche’s SKYSCRAPER-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint inhibitor…
User account | Research To Practice
Research To Practice requires users to log in to view educational content. All content is available without
Management of Stage III Non–Small Cell Lung Cancer – OncoDaily
Management of Stage III Non–Small Cell Lung Cancer / ASCO, cancer, Cleveland Clinic, Hematology, Jame Abraham, Lung cancer, MedOnc, Navneet Singh, non small
Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer
Abstract. Purpose: Breast cancer cells disseminate to distant sites via Tumor Microenvironment of Metastasis (TMEM) doorways. The TIE2 inhibitor rebastinib blocks TMEM doorway function in…
